Lb Pharmaceuticals Inc (LBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | |
| Operating Expenses | 30,404 | 64,830 |
| Operating Income | -30,404 | -64,830 |
| Other Income | 5,200 | 1,729 |
| Pre-tax Income | -25,204 | -63,101 |
| Income Tax | 1 | 1 |
| Net Income Continuous | -25,205 | -63,102 |
| Net Income | $-25,205 | $-63,102 |
| EPS Basic Total Ops | -3.13 | -176.15 |
| EPS Basic Continuous Ops | -3.13 | -176.15 |
| EPS Diluted Total Ops | -3.13 | -176.15 |
| EPS Diluted Continuous Ops | -3.13 | -176.15 |
| EPS Diluted Before Non-Recurring Items | -3.13 | N/A |
| EBITDA(a) | $-29,822 | $-64,773 |